Our new class of antibiotics demonstrate potent and broad-spectrum activity against both Gram-positive and Gram-negative bacteria including many Gram-negative multi-drug resistant (MDR) strains where there is a global rising unmet medical need and large market potential. This focus will enable us to benefit from emerging incentives to bring new antibiotics to market.
We are utilising our proprietary organogold chemistry platform to build a pipeline of novel antibacterials with an initial focus on treating complicated urinary tract infections (cUTI). Auspherix’s pipeline comprises three structurally distinct, small molecule lead series currently in lead optimisation.
As a private company, Auspherix is backed by experienced investors namely Brandon Capital through the Australian Medical Research Commercialisation Fund (MRCF) and UK-based Touchstone Innovations plc (AIM:IVO).
Our Company is located at the Stevenage Bioscience Catalyst facility, UK a world-leading hub for open innovation and centre for fast growing biotech, pharma and medtech businesses.